Clinical Trials Browser

OTHER × Inflammatory Breast Neoplasms × Paclitaxel × Clear all

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT03101748 2026-02-12

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1/2 Terminated

34 enrolled 15 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT02876302 2026-02-04

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Phase 2 Active not recruiting

23 enrolled 18 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02876107 2025-10-10

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

Phase 2 Active not recruiting

42 enrolled

Breast

Breast Neoplasms, Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03515798 2025-09-12

PELICAN

Phase 2 Active not recruiting

52 enrolled

Breast

Inflammatory Breast Neoplasms

NCT02221999 2023-08-29

SHPD002

Phase 2/3 Active not recruiting

250 enrolled

Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT01583426 2020-08-06

GeparSepto

Phase 3 Completed

1,229 enrolled

Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT02879513 2020-03-23

Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy

Phase 3 Unknown

290 enrolled

Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT00513695 2019-08-07

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

Phase 2 Completed

68 enrolled 10 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00006110 2017-07-31

NRR

Phase 2 Completed

82 enrolled 13 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT02125344 2017-07-13

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

Phase 3 Completed

961 enrolled

Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT01426880 2016-02-15

GeparSixto

Phase 2/3 Completed

595 enrolled

Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT00756470 2014-11-17

Phase II Neoadjuvant in Inflammatory Breast Cancer

Phase 2 Terminated

15 enrolled 10 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00072319 2013-03-04

Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

Phase 2 Completed

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Clinical Trials

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

PELICAN

SHPD002

GeparSepto

Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

NRR

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

GeparSixto

Phase II Neoadjuvant in Inflammatory Breast Cancer

Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer